Purdue Ventures invests in antibody-based cancer therapeutics company

TRIO Pharmaceuticals enhances the body’s immune system to effectively attack cancers

2023-04-20

(Press-News.org) WEST LAFAYETTE, Ind. – Purdue Ventures, which manages three funds to support Purdue University-connected startups, has invested $250,000 in TRIO Pharmaceuticals Inc., a cancer immunotherapeutics startup founded by a Purdue University biophysics and structural biology alumnus. The company’s antibody-based therapeutics strengthens the body’s defense, the immune system, to eradicate cancer.

Purdue Ventures’ investment is part of a larger $2.2 million series seed-funding round that includes investments from investor groups in the U.S. and Japan: NuFund Venture Group, SeedFolio, Friedman BioVentures, Tech Coast Angels, Newsight Tech Angels and others.

Shiva Bhowmik, TRIO’s founder and chief operating officer, said traditional approaches to developing anticancer drugs focus on eliminating cancer cells and activating the body’s immune system.

“These approaches don’t lead to the full enhancement of the body’s immunity to fight cancer because there is another bad actor involved: immunosuppressive cells,” he said. “These cells reduce the immune system’s ability to fight infections and diseases like cancer. TRIO Pharmaceuticals is the only company that has figured out how to selectively eliminate this bad actor.

“But if you eliminate just immunosuppressive cells, there isn’t a very strong enhancement of antitumor activity. So, the crux of what TRIO Pharmaceuticals does is to enhance antitumor immunity with a mix of directly eliminating both cancer cells and immunosuppressive cells.”

Bhowmik said Purdue Ventures’ investment and the funding round will allow TRIO to advance its technology and find the best drug candidates to further develop.

“This milestone is very critical for us,” he said. “Once we achieve it, it opens us up for further collaborations with large pharmaceutical companies and the possibility to raise future rounds of funding.”

TRIO has significant ties to Purdue.

“I earned my PhD in biophysics and structural biology from Purdue,” Bhowmik said. “During my tenure, Wayne Hockmeyer gave a talk as a distinguished alumnus of the Department of Biological Sciences. He had founded MedImmune, one of the world’s most renowned biotechnology companies that was eventually acquired by AstraZeneca.

“Wayne’s journey inspired me. He served his country as a commissioned officer in the U.S. Army; he earned his doctorate and founded MedImmune. I was always very inclined to be an entrepreneur, and Wayne’s story inspired me to become an entrepreneur. Coincidentally, the structural biology building was dedicated to Wayne. I’m excited to maintain TRIO’s connections with Purdue through this investment from Purdue Ventures.”

Riley Gibb, associate director of Purdue Ventures, said TRIO Pharmaceuticals is a strong addition to the investment portfolio.

“TRIO is doing groundbreaking work in cancer therapeutics, which captured the interest of the investment committee,” he said. “The company has a unique perspective to address a worldwide problem. That and their connections with Purdue University make them a company we are proud to support and to follow their growth.”

About Purdue Ventures

With almost $20 million under current management, Purdue Ventures manages multiple pools of capital in collaboration with the university ecosystem and local corporations, enabling Purdue startups to improve the world.

About TRIO Pharmaceuticals

TRIO Pharmaceuticals Inc. is a cancer immunotherapeutics company pioneering dual-action drugs to generate immunogenic tumors. TRIO’s innovative antibody drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. TRIO is developing a proprietary platform of dual-action tumor immunity-enhancing drugs aimed at treating cancers of high unmet medical needs by targeting specific antigens on the cancer cells and immunosuppressor cells. TRIO has an experienced team that has developed first-in-class FDA-approved drugs.

Writer/Media contact: Steve Martin, sgmartin@prf.org

Sources: Shiva Bhowmik, shiva@triopharmaceuticals.com, Riley Gibb, rtgibb@prf.org

END

[Attachments] See images for this press release:

ELSE PRESS RELEASES FROM THIS DATE:

Jefferson Lab stays gold by staying green

2023-04-20

NEWPORT NEWS, VA – Finding ways to purchase sustainable products for the work of science has yielded another golden award. The U.S. Department of Energy's Thomas Jefferson National Accelerator Facility has been recognized with a gold-level GreenBuy Award for its purchase of environmentally friendly products in fiscal year 2022. The GreenBuy Award Program honors DOE sites that go beyond the minimum requirements for purchasing products that are energy efficient, water efficient and recycled. Participating sites can qualify for three levels of the award: gold, silver and bronze. “The award is to show our mindset is ...

Evolution of two contagious cancers affecting Tasmanian devils underlines unpredictability of disease threat

2023-04-20

PRESS RELEASE FROM THE UNIVERSITY OF CAMBRIDGE EMBARGOED UNTIL 19:00 BST LONDON TIME/14:00 US EASTERN TIME THURSDAY, 20 APRIL 2023 Paper and photos available at: https://drive.google.com/drive/folders/1YaEEaTCCMRt85NXmCSpeO15YOrIRaXpO?usp=share_link Transmissible cancers, which occur only rarely in the animal kingdom, are spread by the transfer of living cancer cells. In the case of Tasmanian devils, the cells are transferred through biting – a behaviour that is common in devils especially in fights over mates and food. Tasmanian devils are susceptible to two fatal transmissible cancers called devil facial ...

A gene involved in Down syndrome puts the brakes on neurons' activity in mice, new study shows

2023-04-20

Researchers from the University of Michigan have found that an extra copy of a gene in Down syndrome patients causes improper development of neurons in mice. The gene in question, called Down syndrome cell adhesion molecule, or DSCAM, is also implicated in other human neurological conditions, including autism spectrum disorders, bipolar disorder and intractable epilepsy. The cause of Down syndrome is known to be an extra copy of chromosome 21, or trisomy 21. But because this ...

Cracking the case of mitochondrial repair and replacement in metabolic stress

2023-04-20

LA JOLLA (April 20, 2023)—Scientists often act as detectives, piecing together clues that alone may seem meaningless but together crack the case. Professor Reuben Shaw has spent nearly two decades piecing together such clues to understand the cellular response to metabolic stress, which occurs when cellular energy levels dip. Whether energy levels fall because the cell’s powerhouses (mitochondria) are failing or due to a lack of necessary energy-making supplies, the response is the same: get rid of the damaged mitochondria and create new ones. Now, in a study published in Science on April 20, 2023, Shaw and team cracked ...

The climate crisis and biodiversity crisis can’t be approached as two separate things

2023-04-20

Human beings have massively changed the Earth system. Greenhouse-gas emissions produced by human activities have caused the global mean temperature to rise by more than 1.1 degrees Celsius compared to the preindustrial era. And every year, there are additional emissions of carbon dioxide, methane and other greenhouse gases, currently amounting to more than 55 gigatonnes of carbon dioxide equivalent. This unprecedented climate crisis has consequences for the entire planet – the distribution of precipitation ...

Economic growth alone is not enough to eliminate rabies

2023-04-20

Economic growth alone may not be enough to deliver the internationally agreed target to end human deaths from dog mediated rabies, according to new research from the University of Surrey. The study identifies that targeting vulnerable populations and improving responsible pet ownership are urgently needed to eradicate the deadly disease, which has strong associations with poverty. In a landmark study, Surrey researchers investigated whether incidences of rabies are an inevitable consequence of poverty or whether other measures of development, such as healthcare access, can play a role in tackling this preventable disease. Dr ...

PLOS Genetics to launch Microbial Section

2023-04-20

SAN FRANCISCO — PLOS today announced that PLOS Genetics is expanding the scope of its journal with a renamed section called Microbial Genetics. This section will replace the former Prokaryotic Genetics section to emphasize research on microbes more broadly with the aim to publish studies that use genetic approaches to provide insights into how bacteria as well as archaea and their phages/viruses, fungi (including yeasts and filamentous fungi), and protists function and interact with the biotic and abiotic world. PLOS Genetics has an established presence in the fungal genetics community, but this ...

Moffitt researchers discover pathway critical for lymphoma development

2023-04-20

TAMPA, Fla. — MYC proteins are important regulators of cancer cell growth, proliferation and metabolism through their ability to increase the expression of proteins involved in these processes. Deregulation of MYC proteins occurs in more than half of all cancers and is associated with poor patient prognosis and outcomes. Numerous researchers have devoted significant efforts to try to target MYC proteins as a therapeutic approach to treat cancer. However, this has been extremely challenging to date, and other complementary strategies are being investigated. In a new article in Blood Cancer Discovery, which was published simultaneously with a presentation ...

Water arsenic including in public water is linked to higher urinary arsenic totals among the U.S. population

2023-04-20

April 20, 2023-- A new study by researchers at Columbia University Mailman School of Public Health shows that water arsenic levels are linked to higher urinary arsenic among the U.S. population for users of both private wells and public water systems. The findings are published in the journal Environmental Research. Long-term exposure to arsenic even at low and moderate levels can increase the risk of cancer and other types of chronic disease. While drinking water along with diet is a major source ...

UHN Researchers publish ground breaking clinical trial in lung transplantation

2023-04-20

(Toronto, April 20, 2023) Storing donor lungs for transplant at 10 degrees Celsius markedly increases the length of time the organ can live outside the body according to research led by a team of scientists at the Toronto Lung Transplant Program in the Ajmera Transplant Centre at the University Health Network (UHN). The prospective multicenter, nonrandomized clinical trial study of 70 patients demonstrated that donor lungs remained healthy and viable for transplant up to four times longer compared ...

Inhibition of cyclooxygenase-2 upregulates the nuclear factor erythroid 2-related factor 2 signaling pathway to mitigate hepatocyte ferroptosis in chronic liver injury

Purdue Ventures invests in antibody-based cancer therapeutics company

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: